Merck and Moderna maintain a longstanding strategic collaboration on their personalized mRNA cancer vaccine program, most recently reinforced by positive Phase 3 INTerpath-001 trial results announced August 19, 2026, which met recurrence-free survival and distant metastasis-free survival endpoints in resected melanoma when combined with Keytruda. This partnership structure—sharing development costs and profits equally—delivers commercial alignment without the regulatory, valuation, or integration complexities of a full merger or acquisition. Merck’s post-Keytruda growth strategy emphasizes targeted bolt-on deals rather than transformative M&A, while Moderna’s market capitalization and mRNA platform independence reduce acquisition incentives. Trader consensus at 97.5% against a 2026 announcement reflects these fundamentals, though tail risks such as abrupt shifts in competitive oncology landscapes or patent dynamics could theoretically alter incentives before year-end.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · AktualisiertJa
2% Chance
NEU
NEU
31. Dez. 2026
Ja
2% Chance
NEU
NEU
31. Dez. 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a longstanding strategic collaboration on their personalized mRNA cancer vaccine program, most recently reinforced by positive Phase 3 INTerpath-001 trial results announced August 19, 2026, which met recurrence-free survival and distant metastasis-free survival endpoints in resected melanoma when combined with Keytruda. This partnership structure—sharing development costs and profits equally—delivers commercial alignment without the regulatory, valuation, or integration complexities of a full merger or acquisition. Merck’s post-Keytruda growth strategy emphasizes targeted bolt-on deals rather than transformative M&A, while Moderna’s market capitalization and mRNA platform independence reduce acquisition incentives. Trader consensus at 97.5% against a 2026 announcement reflects these fundamentals, though tail risks such as abrupt shifts in competitive oncology landscapes or patent dynamics could theoretically alter incentives before year-end.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Markt eröffnet: Aug 19, 2026, 3:58 PM ET
Volumen
$371Enddatum
31. Dez. 2026Markt eröffnet
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a longstanding strategic collaboration on their personalized mRNA cancer vaccine program, most recently reinforced by positive Phase 3 INTerpath-001 trial results announced August 19, 2026, which met recurrence-free survival and distant metastasis-free survival endpoints in resected melanoma when combined with Keytruda. This partnership structure—sharing development costs and profits equally—delivers commercial alignment without the regulatory, valuation, or integration complexities of a full merger or acquisition. Merck’s post-Keytruda growth strategy emphasizes targeted bolt-on deals rather than transformative M&A, while Moderna’s market capitalization and mRNA platform independence reduce acquisition incentives. Trader consensus at 97.5% against a 2026 announcement reflects these fundamentals, though tail risks such as abrupt shifts in competitive oncology landscapes or patent dynamics could theoretically alter incentives before year-end.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Volumen
$371Enddatum
31. Dez. 2026Markt eröffnet
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...Merck and Moderna maintain a longstanding strategic collaboration on their personalized mRNA cancer vaccine program, most recently reinforced by positive Phase 3 INTerpath-001 trial results announced August 19, 2026, which met recurrence-free survival and distant metastasis-free survival endpoints in resected melanoma when combined with Keytruda. This partnership structure—sharing development costs and profits equally—delivers commercial alignment without the regulatory, valuation, or integration complexities of a full merger or acquisition. Merck’s post-Keytruda growth strategy emphasizes targeted bolt-on deals rather than transformative M&A, while Moderna’s market capitalization and mRNA platform independence reduce acquisition incentives. Trader consensus at 97.5% against a 2026 announcement reflects these fundamentals, though tail risks such as abrupt shifts in competitive oncology landscapes or patent dynamics could theoretically alter incentives before year-end.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen